Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD
| Autor: | Niels Kruse, Matthias Schmitz, Mohsin Shafiq, Katrin Thüne, Nadine Gotzman, Inga Zerr, João Ricardo Mendes de Oliveira, Brit Mollenhauer, Saima Zafar, José Eriton Gomes da Cunha, Franc Llorens |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Pathology Neurology tau Proteins cerebrospinal fluid [Amyloid beta-Peptides] Diagnostic tools Creutzfeldt-Jakob Syndrome Screening analysis Diagnosis Differential methods [Luminescent Measurements] Alzheimer Disease Biological fluids medicine Electrochemiluminescence Humans Clinical quality ddc:610 cerebrospinal fluid [Peptide Fragments] Immunoassay Amyloid beta-Peptides business.industry methods [Immunoassay] cerebrospinal fluid [Creutzfeldt-Jakob Syndrome] amyloid beta-protein (1-42) Peptide Fragments cerebrospinal fluid [Alzheimer Disease] cerebrospinal fluid [Biomarkers] cerebrospinal fluid [tau Proteins] Csf biomarkers Luminescent Measurements alpha-Synuclein Neurology (clinical) Differential diagnosis business Biomarkers cerebrospinal fluid [alpha-Synuclein] |
| Zdroj: | Journal of neurology 262(10), 2305-2311 (2015). doi:10.1007/s00415-015-7837-x |
| DOI: | 10.1007/s00415-015-7837-x |
| Popis: | The identification of reliable diagnostic tools for the differential diagnosis between sporadic Creutzfeldt-Jakob Disease (sCJD) and Alzheimer's disease (AD) remains impeded by the existing clinical, neuropathological and molecular overlap between both diseases. The development of new tools for the quantitative measurement of biomarkers is gaining experimental momentum due to recent advances in high-throughput screening analysis and with the optimization of assays for their quantification in biological fluids, including cerebrospinal fluid (CSF). Electrochemiluminescence (ECL)-based immunoassays have demonstrated to achieve clinical quality performance in a variety of sample types due to its high sensitivity and dynamic range. Here, we quantified the CSF levels of Tau-protein, β-amyloid 1-42 (Aβ42) and α-synuclein, as important biomarkers in CSF used in the differential diagnosis of neurodegenerative disorders in 12 AD, 12 sCJD and 12 control cases by singleplex ECL-based technology. Its performance has been compared to classical enzyme-linked immunosorbent assays (ELISA) to confront their clinical accuracy. ECL-based technology validates previous data obtained with ELISA and presents a higher performance in the discrimination of three analysed groups as determined by increased area under the curve (AUC) values for the three biomarkers. Importantly, α-synuclein levels detected by ECL allow an excellent discrimination between sCJD cases and AD and control cases, unveiling a new clinical approach for the differential diagnosis of sCJD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|